Michael Davidson's most recent trade in Tenax Therapeutics Inc was a trade of 80,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tenax Therapeutics Inc | Michael Davidson Harvey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| BioAge Labs Inc. | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 38,394 | 402,699 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 38,394 | 0 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 38,394 | 38,394 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 30,992 | 364,305 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 Mar 2025 | 12,258 | 390,441 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 670,467 | 670,467 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 123,529 | 123,529 | - | - | Ordinary Shares | |
| Silence Therapeutics Plc -... | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,000 | 48,000 | - | - | Share Option (Right to Buy) | |
| Tenax Therapeutics Inc | Davidson Michael Harvey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Oct 2024 | 15,000 | 85,000 | - | - | Warrant (right to buy) | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 16.27 per share. | 20 Aug 2024 | 5,000 | 209,784 | - | 16.3 | 81,350 | Ordinary Shares |
| Tenax Therapeutics Inc | Michael Harvey Davidson | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 08 Aug 2024 | 47,500 | 47,500 | - | - | Pre-Funded Warrant | |
| Tenax Therapeutics Inc | Michael Harvey Davidson | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 08 Aug 2024 | 25,000 | 25,000 | - | - | Warrant | |
| Tenax Therapeutics Inc | Michael Harvey Davidson | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 08 Aug 2024 | 2,500 | 2,881 (0%) | 0% | - | Common Stock | |
| NewAmsterdam Pharma Compan... | Michael Harvey Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.26 per share. | 20 Jun 2024 | 5,000 | 204,784 | - | 17.3 | 86,309 | Ordinary Shares |
| BioAge Labs Inc. | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 33,986 | 33,986 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc. | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| NewAmsterdam Pharma Compan... | Davidson Harvey Michael | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 1,039,939 | 1,039,939 | - | - | Option (right to buy) | |
| Lisata Therapeutics Inc | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 65,430 | 209,753 (1%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2021 | 37,735 | 144,323 (1%) | 0% | 0 | Common Stock | |
| Minerva Neurosciences Inc | Michael Davidson | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 85,000 | 85,000 | - | - | Employee Stock Option (right to buy) | |
| Lisata Therapeutics Inc | Michael H. Davidson | Director | Purchase of securities on an exchange or from another person at price $ 1.80 per share. | 09 Sep 2020 | 55,525 | 106,588 (1%) | 0% | 1.8 | 99,945 | Common Stock |
| Lisata Therapeutics Inc | Michael H. Davidson | Director | Grant, award, or other acquisition of securities at price $ 2.35 per share. | 28 Jul 2020 | 51,063 | 51,063 (0%) | 0% | 2.3 | 119,998 | Common Stock |